CRISPR Technology and its impact on the regulatory landscape

by EMMA International | Feb 16, 2024 | Cells, Compliance, FDA, Gene and Cell Therapies, Regulatory, Requirements

Whitepaper_CRISPR Techology_February 2024 (3)

As researchers explore the potential of CRISPR in the development of gene therapies, the regulatory landscape becomes a critical aspect of ensuring the safety and efficacy of these groundbreaking treatments. In this White Paper, we will delve into how the FDA navigates and regulates CRISPR technology in the context of gene therapy. To learn more about how EMMA International can support your cell & gene therapy, click here!

EMMA International

EMMA International Consulting Group, Inc. is a global leader in FDA compliance consulting. We focus on quality, regulatory, and compliance services for the Medical Device, Combination Products, and Diagnostics industries.